Annexon (NASDAQ:ANNX - Get Free Report)'s stock had its "overweight" rating reissued by investment analysts at Cantor Fitzgerald in a report released on Wednesday, Benzinga reports.
ANNX has been the topic of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Annexon in a report on Wednesday, March 27th. Bank of America lifted their price objective on Annexon from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Thursday, March 28th. Wells Fargo & Company lifted their price objective on Annexon from $11.00 to $12.00 and gave the stock an "overweight" rating in a report on Wednesday, March 27th. JPMorgan Chase & Co. lifted their price objective on Annexon from $11.00 to $13.00 and gave the stock an "overweight" rating in a report on Monday, April 1st. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price objective on shares of Annexon in a report on Thursday, April 11th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Annexon currently has a consensus rating of "Buy" and a consensus price target of $14.43.
Get Our Latest Stock Analysis on Annexon
Annexon Price Performance
NASDAQ ANNX traded up $0.01 during trading hours on Wednesday, reaching $4.45. 3,605,172 shares of the stock traded hands, compared to its average volume of 1,522,782. The stock has a 50 day simple moving average of $5.71 and a two-hundred day simple moving average of $4.13. Annexon has a 1 year low of $1.57 and a 1 year high of $8.40. The company has a market cap of $400.63 million, a price-to-earnings ratio of -2.65 and a beta of 1.14.
Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings results on Tuesday, March 26th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. On average, sell-side analysts forecast that Annexon will post -1.36 EPS for the current fiscal year.
Insider Activity at Annexon
In other Annexon news, CEO Douglas Love sold 5,782 shares of Annexon stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $5.54, for a total transaction of $32,032.28. Following the sale, the chief executive officer now directly owns 196,121 shares of the company's stock, valued at approximately $1,086,510.34. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 8,940 shares of company stock worth $49,514 in the last 90 days. Company insiders own 19.11% of the company's stock.
Institutional Trading of Annexon
Large investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in Annexon during the 3rd quarter valued at approximately $52,000. Tower Research Capital LLC TRC boosted its position in shares of Annexon by 53.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,924 shares of the company's stock worth $54,000 after purchasing an additional 4,141 shares in the last quarter. Forefront Analytics LLC boosted its position in shares of Annexon by 18.3% in the 3rd quarter. Forefront Analytics LLC now owns 31,680 shares of the company's stock worth $75,000 after purchasing an additional 4,890 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Annexon in the 4th quarter worth approximately $221,000. Finally, Lighthouse Investment Partners LLC bought a new stake in shares of Annexon in the 4th quarter worth approximately $306,000.
About Annexon
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Further Reading
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
